Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapy

Gastroenterology

Volumn 127, Issue 5, 2004, Pages 1558-1564

  Lichtenstein, Gary R ^a,b  

^a Department of Medicine   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE;

ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; COLON CROHN DISEASE; DRUG DOSE REGIMEN; DRUG EFFECT; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LABORATORY TEST; LEUKOCYTE; LEUKOCYTE COUNT; LEUKOPENIA; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 7644238430     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2004.09.061     Document Type: Article

References (38)

1. D. Pearson, G.R. May, G.H. Fick, L.R. Sutherland Azathioprine and 6-mercaptopurine in Crohn's disease a meta analysis Ann Intern Med 123 1995 132 142
2. J.M.T. Willoughby, J. Beckett, P.J. Kumar, A.M. Dawson Controlled trial of azathioprine in Crohn's disease Lancet 2 1971 944 947
3. J. Rhodes, D. Bainton, P. Beck, H. Campbell Controlled trial of azathioprine in Crohn's disease Lancet 2 1971 1273 1276
4. M. Klein, H.J. Binder, M. Mitchell, R. Aaronson, H. Spiro Treatment of Crohn's disease with azathioprine a controlled evaluation Gastroenterology 66 1974 916 922
5. R.W. Summers, D.M. Switz, J.T. Sessions Jr, J.M. Becktel, W.R. Best, F.J. Kern, J.W. Singleton National cooperative Crohn's disease study results of drug treatment Gastroenterology 77 1979 847 869
6. D.H. Present, B.I. Korelitz, N. Wisch, J.L. Glass, D.B. Sachar, B.S. Pasternack Treatment of Crohn's disease with 6-mercaptopurine a long-term randomized, double-blind study N Engl J Med 302 1980 981 987
7. K. Ewe, A.G. Press, C.C. Singe, M. Stufler, B. Ueberschaer, G. Hommel, K.H. Meyer zum Buschenfelde Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease Gastroenterology 105 1993 367 372
8. S. Candy, J. Wright, M. Gerber, G. Adams, M. Gering, R. Goodman A controlled double blind study of azathioprine in the management of Crohn's disease Gut 37 1995 674 678
9. R. Oren, M. Moshkowitz, S. Odes, S. Becker, D. Keter, I. Pomeranz, C. Shirin, I. Reisfeld, E. Broide, A. Lavy, A. Fich, R. Eliakim, J. Patz, Y. Villa, N. Arber, T. Gilat Methotrexate in chronic active Crohn's disease a double-blind, randomized, Israeli multicenter trial Am J Gastroenterol 92 1997 2203 2209
10. L. Lennard, J.A. Van Loon, R.M. Weinshilboun Pharmacogenetics of acute azathioprine toxicity relationship to thiopurine methyltransferase genetic polymorphism Clin Pharmacol Ther 46 1989 149 154
11. B.A. Kaskas, E. Louis, U. Hindorf, E. Schaeffeler, J. Deflandre, F. Graepler, K. Schmiegelow, M. Gregor, U.M. Zanger, M. Eichelbaum, M. Schwab Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine Gut 52 2003 140 142
12. H.I. McLeod, F.Y. Krynetski, M.V. Relling, W.E. Evans Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia Leukemia 14 2000 567 572
13. J.N. Stolk, A.M. Boerbooms, R.A. de Abreu, D.G. de Koning, H.J. van Beusekom, W.H. Muller, L.B. van de Putte Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis Arthritis Rheum 41 1998 1858 1866
14. J.F. Colombel, N. Ferrari, H. Debuysere, P. Marteau, J.P. Gendre, B. Bonaz, J.C. Soule, R. Modigliani, Y. Touze, P. Catala, C. Libersa, F. Broly Genotypic analysis of thiopurine S-methyl transferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy Gastroenterology 118 2000 1025 1030
15. M. Regueiro, H. Mandini Determination of thiopurine methyltransferase genotype or phenotype optimizes initial therapy of azathioprine for the treatment of Crohn's disease J Clin Gastroenterol 35 2002 240 244
16. H. Corominas, H. Domenech, D. Gonzalez, C. Diaz, M. Roca, M.A. Garcia Gonzalez, S. Pena, M. Baiget Allelic variants of the thiopurine S-methyltransferase deficiency in patients with ulcerative colitis and healthy controls Am J Gastroenterol 95 2000 2313 2317
17. A.J. Black, H.L. McLeod, H.A. Capell, R.H. Powrie, L.K. Matowe, S.C. Pritchard, E.S. Collie-Duguid, D.M. Reid Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine Ann Intern Med 129 1998 716 718
18. M. Seddik, F. Texier, N. Ferrari, A. Cortot, C. Libersa, F. Broly, J.F. Colombel Thiopurine S-methyltransferase genotyping does not predict azathioprine-induced myelosuppression in Crohn's disease (abstr) Gastroenterology 124 2003 A311
19. W. Curvers, L. Derijks, P. Stokkers, E. Vogels, J. de Gast, I. Pronk, A. van Kampen, S. van Deventer, D. Hommes No predictive value of TPMT genotyping for leukopenia or hepatotoxicity during azathioprine therapy for inflammatory bowel disease (abstr) Gastroenterology 124 2003 A377
20. J.L. Snow, L.E. Gibson A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients J Am Acad Dermatol 32 1995 114 116
21. J.L. Snow, L.E. Gibson The role in genetic variation in thiopurine methyl transferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients Arch Dermatol 131 1995 193 197
22. A. Ansley, L. Lennard, S.C. Mayou, J.D. Kirby Pancytopenia related to azathioprine--an enzyme deficiency caused by a common genetic polymorphism a review J R Soc Med 85 1992 752 756
23. L. Lennard, C.A. Rees, J.S. Lilleyman, J.L. Maddocks Childhood leukaemia a relationship between intracellular 6-mercaptopurine metabolites and neutropenia Br J Clin Pharmacol 16 1983 359 363
24. H.L. McLeod, M.V. Relling, Q. Liu, C.H. Pui, W.E. Evans Polymorphic thiopurine methyl transferase in erythrocytes is indicative of activity in leukaemic blasts from children with acute lymphoblastic leukaemia Blood 85 1995 1897 1902
25. B. Borstrom, G. Erdman Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukaemia Am J Pediatr Hematol Oncol 15 1993 80 86
26. C. Cuffari, Y. Theoret, S. Latour, G. Seidman 6-Mercaptopurine metabolism in Crohn's disease correlation with efficacy and toxicity Gut 39 1996 401 406
27. C. Cuffari, S. Hunt, T.M. Bayless Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease correlation with treatment efficacy Aliment Pharmacol Ther 14 2000 1009 1014
28. C. Cuffari, S. Hunt, T.M. Bayless Utilisation of erythrocyte 6-thioguanine metabolite levels to optimize azathioprine therapy in patients with inflammatory bowel disease Gut 48 2001 642 646
29. M.C. Dubinsky, S. Lamothe, H.Y. Yang, S.R. Targan, D. Sinnett, Y. Theoret, E.G. Seidman Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease Gastroenterology 118 2000 705 713
30. W.J. Sandborn, W.J. Tremaine, D.C. Wolf, S.R. Targan, C.A. Sninsky, L.R. Sutherland, S.B. Hanauer, J.W. McDonald, B.G. Feagan, R.N. Fedorak, K.L. Isaacs, M.G. Pike, D.C. Mays, J.J. Lipsky, S. Gordon, C.S. Kleoudis, R.H. Murdock Jr Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group Gastroenterology 117 1999 527 535
31. P.W. Lowry, C.I. Franklin, A.I. Weaver, M.G. Pike, D.C. Mays, W.J. Tremaine, J.J. Lipsky, W.J. Sandborn Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease Gut 49 2001 665 670
32. J. Belaiche, J.P. Desager, Y. Horsmans, E. Louis Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn's disease Scand J Gastroenterol 36 2001 71 76
33. T. Colonna, B.I. Korelitz The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease Am J Gastroenterol 89 1994 362 366
34. W.J. Sandborn, E.C. Van Os, B.J. Zins, W.J. Tremaine, D.C. Mays, J.J. Lipsky An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease Gastroenterology 109 1995 1808 1817
35. S. Campbell, S. Ghosh Is neutropenia required for effective maintenance of remission during azathioprine therapy in inflammatory bowel disease? Eur J Gastroenterol Hepatol 13 2001 1073 1076
36. T.M. Wallace, S.J. Veldhuyzen van Zanten Frequency of use and standards of care for the use of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease a systematic review of the literature and a survey of Canadian gastroenterologists Can J Gastroenterol 15 2001 21 28
37. J. Winter, A. Walker, O. Shapiro, O. Gaffney, R.J. Spooner, P.R. Mills Cost-effectiveness of thiopurine methyl transferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease Aliment Pharmacol Ther 10 2004 593 599
38. L. Sebbag, P. Boucher, P. Davelu, P. Boissonnat, G. Champsaur, J. Ninet, G. Dureau, J.F. Obadia, J.J. Vallon, J. Delaye Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipients Transplantation 69 2000 1524 1527